Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s share price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$13.17 and traded as high as C$15.00. Fennec Pharmaceuticals shares last traded at C$14.79, with a volume of 286 shares trading hands.
Fennec Pharmaceuticals Trading Up 2.0%
The stock has a market cap of C$513.76 million, a P/E ratio of -51.00 and a beta of 3.52. The company has a 50 day simple moving average of C$13.17 and a 200 day simple moving average of C$11.20.
Insider Buying and Selling
In other news, Director Chris Anigeron Rallis sold 8,346 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of C$9.67, for a total value of C$80,705.82. Following the sale, the director directly owned 61,314 shares in the company, valued at C$592,906.38. This trade represents a 11.98% decrease in their ownership of the stock. Also, Director Rostislav Christov Raykov sold 9,747 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of C$13.23, for a total transaction of C$128,952.81. Following the completion of the sale, the director directly owned 2,746,104 shares in the company, valued at approximately C$36,330,955.92. This represents a 0.35% decrease in their position. 16.20% of the stock is owned by company insiders.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
See Also
- Five stocks we like better than Fennec Pharmaceuticals
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
